What are the primary causes of secondary hyperparathyroidism?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Primary Causes of Secondary Hyperparathyroidism

The primary causes of secondary hyperparathyroidism are chronic kidney disease, vitamin D deficiency, phosphate retention, and insufficient calcium intake or absorption. 1, 2

Chronic Kidney Disease (CKD)

CKD is the most common cause of secondary hyperparathyroidism through several interrelated mechanisms:

  • Phosphate retention: As kidney function declines, the ability to excrete phosphate decreases, leading to hyperphosphatemia 1

    • Even in early CKD (Stage 3), transient increases in serum phosphorus can stimulate PTH secretion
    • The elevated PTH increases phosphate excretion, often normalizing serum phosphorus levels but at the expense of elevated PTH
  • Decreased calcitriol (1,25(OH)₂D₃) production: 1, 2

    • Impaired kidney function reduces the conversion of 25(OH)D to active 1,25(OH)₂D₃
    • Decreased calcitriol leads to reduced intestinal calcium absorption and hypocalcemia
    • Low calcitriol directly affects parathyroid gland function
  • Receptor abnormalities in parathyroid glands: 1, 2

    • Decreased vitamin D receptor (VDR) expression
    • Reduced calcium-sensing receptor (CaR) expression
    • These changes make parathyroid glands more resistant to vitamin D and calcium

Vitamin D Deficiency

  • Vitamin D insufficiency/deficiency is highly prevalent (80-90%) in CKD patients 1

  • Causes of vitamin D deficiency in CKD include:

    • Sedentary lifestyle with reduced sun exposure
    • Limited intake of vitamin D-rich foods
    • Reduced endogenous synthesis with uremia
    • Urinary losses of 25(OH)D and vitamin D-binding protein in nephrotic syndrome 1
  • Even in patients with normal kidney function, vitamin D deficiency can lead to secondary hyperparathyroidism 3

Calcium Deficiency

  • Insufficient calcium intake or absorption can cause secondary hyperparathyroidism even with normal kidney function and vitamin D levels 3
  • Low serum calcium directly stimulates PTH secretion
  • This form of secondary hyperparathyroidism can be diagnosed through a "calcium challenge" - providing calcium supplementation and observing normalization of PTH levels 3

Other Causes

  • Malabsorption syndromes affecting calcium and vitamin D absorption
  • Medications that affect calcium, phosphorus, or vitamin D metabolism
  • Phosphate loading (high phosphate diet) 1

Pathophysiological Cascade

  1. Initial trigger (kidney dysfunction, vitamin D deficiency, or calcium deficiency)
  2. Decreased serum calcium and/or increased serum phosphorus
  3. Increased PTH secretion (initially adaptive)
  4. Parathyroid gland hyperplasia
  5. Progressive resistance to normal regulatory mechanisms
  6. Persistent elevation of PTH despite treatment

Clinical Implications

Uncontrolled secondary hyperparathyroidism can lead to:

  • Renal osteodystrophy and bone disease
  • Vascular and soft tissue calcification
  • Increased cardiovascular morbidity and mortality
  • Neurological disturbances
  • Hematological abnormalities 2, 4

Understanding the underlying cause is essential for appropriate management, which may include dietary modifications, phosphate binders, vitamin D supplementation, calcimimetics, and in severe cases, parathyroidectomy 2, 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Secondary Hyperparathyroidism in Chronic Kidney Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Calcium Challenge to Confirm Secondary Hyperparathyroidism Caused by Decreased Calcium Intake.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.